Across TCGA pan-cancer cohorts, TRPV2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRPV2 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRPV2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRPV2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where TRPV2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.982	0.844	.003	18	view →
COAD	DFS	Tertile	All	0.870	1.000	.040	6	view →
HNSC	DFS	Quartile	II,III,IV	0.903	1.000	.029	5	view →
PDAC	DFS	Median	All	0.229	0.351	.047	4	view →
LSCC	OS	Median	II,III,IV	0.631	0.849	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TRPV2 tumor-vs-normal RNA expression · all TRPV2 data types